Who
Daniel M. Junius
Director
Company insider
Files Form 4 as: Director, IDEXX Laboratories; Director, Crescent Biopharma; Chief Executive Officer, Immunogen; Director, Vitae Pharmaceuticals.
In numbers
- Trades disclosed
- 233
- Buys
- 11
- Sells
- 29
- Bought
- $509K
- Sold
- $15.0M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 8 Jun 2006
- Last trade
- 12 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 May 2026filed 14 May 2026 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —525 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —234 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —525 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —234 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | IDXX IDEXX LaboratoriesDiagnostics & Labs | SEC FORM 4 Code M | —257 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —257 | filing |
| 7 May 2026filed 11 May 2026 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —257 | filing |
| 7 May 2026filed 11 May 2026 | IDXX IDEXX LaboratoriesDiagnostics & Labs | SEC FORM 4 Code M | —257 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —1,404 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —1,279 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | IDXX IDEXX LaboratoriesDiagnostics & Labs | SEC FORM 4 Code M | $345K1,404 at $245.79 | filing |
| 13 May 2025filed 14 May 2025 | IDXX IDEXX LaboratoriesDiagnostics & Labs | SEC FORM 4 Code M | $363K1,279 at $283.59 | filing |
| 13 May 2025filed 14 May 2025 | IDXX IDEXX LaboratoriesDiagnostics & Labs | SEC FORM 4 Sold | $1.4M2,683 at $506.41 | filing |
| 7 May 2025filed 8 May 2025 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —600 at $0.00 | filing |
| 7 May 2025filed 8 May 2025 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —257 at $0.00 | filing |
| 6 May 2025filed 8 May 2025 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —262 at $0.00 | filing |
| 6 May 2025filed 8 May 2025 | IDXX IDEXX LaboratoriesDiagnostics & Labs | SEC FORM 4 Code M | —262 at $0.00 | filing |
| 6 May 2024filed 8 May 2024 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —609 at $0.00 | filing |
| 6 May 2024filed 8 May 2024 | IDXX IDEXX Laboratoriesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —262 at $0.00 | filing |
| 1 May 2024filed 1 May 2024 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
IDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth?IDXX · insidermonkey.com · 22 Oct 2026
0 headlines in the last 90 days name Daniel M. Junius; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.